Drug · Small Molecule
Diethylstilbestrol
CI-DRUG-00000663Explore in graph →CHEMBL411 Approved
Regulatory
Approvals (7)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| CA Health Canada | — | Marketed in Canada as STILBESTROL TABLETS 0.5 MG (DIN 02100304) under ATC L02AA01 DIETHYLSTILBESTROL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Cancelled Post Marketsince Feb 23, 2009 | Apr 1, 1997 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as STILBESTROL TABLETS 0.1 MG (DIN 02091488) under ATC L02AA01 DIETHYLSTILBESTROL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Cancelled Post Marketsince Feb 23, 2009 | Jul 30, 1996 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as STILBESTROL TABLETS 1.0 MG (DIN 02091461) under ATC L02AA01 DIETHYLSTILBESTROL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawn |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 15 days agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Withdrawn | Phase 3 | 0 | 0 | 1 | 1 | 7 | CA | — | 2002-12 |
| Malignant Prostate Neoplasm | Phase3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2002-12 |
- Source
- clinicaltrials
- Layer
- derived (computed by CancerIndex)
Curated evidence
Clinical evidence (0)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
Data not yet available
Clinical trials
Trials with this intervention (1)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00316927 | Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer | completed | Phase 3 | 260 | St. Bartholomew's HospitalOTHER | 1 | Jun 26, 2013 | clinicaltrials |